Providing Economic Support in Bayer’s $180 Million Patent Infringment Damages Award

A team from NERA analyzed Bayer HealthCare's reasonable royalty damages caused by the infringing use of a Bayer patented invention in a biological treatment for hemophilia and provided testimony on this analysis at the US District Court trial.